Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Nov 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 223
  • No of Figures: 35

Asia Pacific Chinese Hamster Ovary Cells Cho Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 77,040.79 Thousand
Diagram Market Size (Forecast Year)
USD 159,123.92 Thousand
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others) - Industry Trends and Forecast to 2030.

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Analysis and Insights

The Asia-Pacific Chinese Hamster Ovary (CHO) market is a vital component of the biopharmaceutical industry, driven by the escalating demand for biologics and therapeutic proteins. CHO cells are a preferred choice for biopharmaceutical production due to their ability to efficiently express complex proteins with proper post-translational modifications.

Asia-Pacific Chinese Hamster Ovary (CHO) Cells MarketAsia-Pacific Chinese Hamster Ovary (CHO) Cells Market

One of the major drivers for the Asia-Pacific Chinese Hamster Ovary (CHO) market is the growing demand for biopharmaceuticals. CHO cells are widely used in the production of biopharmaceuticals, including monoclonal antibodies, vaccines, and other therapeutic proteins. With an aging population and increasing healthcare needs, there is a rising demand for these advanced medicines across Asia-Pacific. CHO cells offer a reliable and efficient platform for the large-scale production of biopharmaceuticals, making them a critical component of the biomanufacturing process. As a result, the Asia-Pacific CHO cell market is experiencing steady growth as pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines, further fueling the adoption of CHO cell-based production systems. This trend is expected to continue, making the Asia-Pacific CHO cell market a significant player in the global biopharmaceutical industry.

However, One of the challenges faced by the Asia-Pacific Chinese Hamster Ovary Cells (CHO) market is regulatory complexity and compliance, which can impact the development and production of biopharmaceuticals.

The Asia-Pacific Chinese Hamster Ovary (CHO) cells market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.9% in the forecast period of 2023 to 2030 and is expected to reach USD 159,123.92 Thousand by 2030 from USD 77,040.79 thousand in 2022.

Asia-Pacific Chinese Hamster Ovary (CHO) cells market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers that propelled the demand of the market in the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Thousand

Segments Covered

Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others)

Countries Covered

China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific

Market Players Covered

Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others. 

Market Definition

Chinese Hamster Ovary (CHO) cells are a type of mammalian cell line commonly used in biotechnology and biomedical research, particularly in the field of cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Dynamics

Drivers

  • Rising use of CHO cells in the genetic study

The rising use of CHO cells in genetic studies is a significant driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells have gained prominence in genetic research due to their adaptability and versatility in genetic manipulation and expression systems. Researchers and biotechnologists across Asia-Pacific are increasingly relying on CHO cells to investigate various aspects of genetics, including gene expression, genome editing, and functional genomics.

CHO cells provide a stable and well-characterized platform for genetic studies, making them an essential resource for understanding gene function, protein expression, and the development of new therapeutic agents. This heightened interest in genetic research using CHO cells not only fuels the demand for CHO cells but also drives innovations in biotechnology and genetic engineering techniques. Consequently, the Asia-Pacific CHO cell market is experiencing growth as it caters to the expanding needs of the scientific community engaged in genetic research and biotechnology, further solidifying its position in the life sciences sector.

  • Growing demand for biopharmaceuticals

The growing demand for biopharmaceuticals is a key driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells play a vital role in the production of biopharmaceuticals, such as monoclonal antibodiesvaccines, and therapeutic proteins. With an aging population and increasing healthcare needs in Asia-Pacific, there is a rising demand for these advanced medicines. CHO cells offer a reliable and efficient platform for large-scale biopharmaceutical production, making them indispensable for the biomanufacturing process. As pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines, the Asia-Pacific CHO cell market is experiencing steady growth, reinforcing its crucial role in the biopharmaceutical industry.

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market

Opportunity

  • Continuous development of cell culture technologies

The continuous development of cell culture technologies is a critical aspect of biopharmaceutical manufacturing and biotechnology research. These advancements play a pivotal role in improving the production of biological drugs, vaccines, and other biotechnological products. The benefits of ongoing developments in cell culture technologies are

Enhanced Cell Line Development: One of the primary areas of focus in cell culture technology is the development of high-productivity cell lines. Scientists are continually refining methods for selecting, engineering, and optimizing mammalian cell lines, including CHO cells. This involves genetic modifications to increase cell growth rates, protein expression levels, and product quality attributes. These advancements result in more efficient and cost-effective biopharmaceutical production.

Improved Culture Media: Cell culture media are essential for providing cells with the necessary nutrients, growth factors, and environmental conditions for optimal growth and protein expression. Ongoing research aims to develop advanced culture media formulations that enhance cell viability, productivity, and product quality while minimizing production costs. This includes the optimization of chemically defined media to reduce reliance on animal-derived components, improving medium recycling strategies, and tailoring media for specific cell lines and biological products.

Restraints/Challenges

  • Time-consuming and inconsistency in the CHO cell line development process

The Asia-Pacific Chinese Hamster Ovary (CHO) market faces the challenge of a time-consuming and often inconsistent CHO cell line development process. Developing stable and high-yielding CHO cell lines for biopharmaceutical production can be a lengthy and resource-intensive endeavor. Variability in cell line performance and characteristics can lead to unpredictability in production, which affects the overall efficiency and cost-effectiveness of biopharmaceutical manufacturing.

The need to optimize and characterize cell lines, select appropriate clones, and achieve consistent productivity levels can extend development timelines and increase operational costs. This challenge not only affects time-to-market for new biopharmaceuticals but also adds complexity to regulatory compliance and quality assurance efforts. Consequently, addressing the time-consuming and inconsistent nature of the CHO cell line development process is essential to enhance the competitiveness of the Asia-Pacific CHO cell market in the biopharmaceutical industry.

  • High cost of CHO cell-based production  

The high cost of CHO cell-based production is a significant restraint in the biopharmaceutical manufacturing industry. Several factors contribute to the elevated costs are mentioned below.

The upstream process in CHO cell-based production is complex. It involves the cultivation of mammalian cells in bioreactors, which necessitates strict control over various parameters such as temperature, pH, oxygen levels, and nutrient supply. Maintaining these optimal conditions for cell growth and protein expression requires specialized equipment and skilled personnel, adding to the overall cost.

Cell line development is another resource-intensive step. Creating highly productive CHO cell lines involves selecting suitable cells and genetically modifying them to express the desired therapeutic protein efficiently. This process involves substantial research efforts, extensive genetic engineering, and rigorous screening, all of which demand time and resources.

In addition, the cost of culture media and nutrients for CHO cells is a significant contributor. These cells require specific growth media containing essential nutrients, growth factors, and supplements. The expense of procuring these high-quality culture media can accumulate significantly over large-scale production runs. Researchers continually work on optimizing media formulations to reduce costs while maintaining cell performance.

Recent Developments

  • In July 2023, Lonza has introduced the TheraPRO CHO Media System, an innovative cell culture solution designed to streamline procedures and enhance both productivity and protein quality, particularly in conjunction with GS-CHO cell lines. This product launch is aimed at assisting pharmaceutical and biotechnology enterprises in their efforts to produce therapeutic proteins of higher quality and expedite their time-to-market
  • In October 2022, after the favorable reception of the Gibco Freedom CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific collaborated once more to create an enhanced solution: the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This advanced platform enables users to establish cell lines suitable for clinical development, even without possessing their own initial cells, vectors, or prior expertise in the domain. Leveraging their profound knowledge in cell line and process development, ProBioGen has significantly enhanced the performance of the Freedom ExpiCHO-S Kit

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Scope

Asia-Pacific Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end-user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Services
  • Products

On the basis of type, the Asia-Pacific  Chinese Hamster Ovary (CHO) market is segmented into services and product.

System

  • Metabolic Selection System
  • Antibiotic Selection System
  • Others

On the basis of systems, the Asia-Pacific  Chinese Hamster Ovary (CHO) market is segmented into metabolic selection system, antibiotic selection system, and others.

Application

  • Biologics
  • Medical Research

On the basis of application, the Asia-Pacific  Chinese Hamster Ovary (CHO) market is segmented into  biologics and medical research.

End-User

  • Biopharmaceutical Companies
  • Biotechnology Companies
  • Clinical Development and Manufacturing Organizations
  • Clinical Research Organizations
  • Academic Institutes and Research Organizations
  • Others

On the basis of end-user, the Asia-Pacific  Chinese Hamster Ovary (CHO) market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and others.

Distribution Channel

  • Direct Tenders
  • Retail Sales
  • Others

On the basis of distribution channel, the Asia-Pacific  Chinese Hamster Ovary (CHO) market is segmented into direct tenders, retail sales, and others.

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights

The Asia-Pacific Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end-user, and distribution channel.

The countries covered in this market report are China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific

China dominates Asia-Pacific region and expected to grow with the highest CAGR in the forcast period due to country's strong research and development capabilities in biopharmaceutical industries.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Share Analysis

Asia-Pacific Chinese Hamster Ovary (CHO) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific Chinese Hamster Ovary (CHO) cells market.

Some of the major players operating in the Asia-Pacific Chinese Hamster Ovary (CHO) cells market are Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others. among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 BY TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET, REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING USE OF CHO CELLS IN THE GENETIC STUDY

6.1.2 GROWING DEMAND FOR BIOPHARMACEUTICALS

6.1.3 RISING INVESTMENTS IN BIOTECHNOLOGY R&D

6.1.4 RISING DEMAND FOR MONOCLONAL ANTIBODIES

6.2 RESTRAINTS

6.2.1 HIGH-COST OF CHO CELL-BASED PRODUCTION

6.2.2 STRICT REGULATORY REQUIREMENTS FOR CHO CELL-BASED PRODUCTION

6.3 OPPORTUNITIES

6.3.1 CONTINUOUS DEVELOPMENT OF CELL CULTURE TECHNOLOGIES

6.3.2 RISING NUMBER OF APPLICATIONS OF CHO CELLS

6.4 CHALLENGES

6.4.1 TIME-CONSUMING AND INCONSISTENCY IN THE CHO CELL LINE DEVELOPMENT PROCESS

6.4.2 CONTAMINATION RISK OF CHO CELL CULTURES

7 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE

7.1 OVERVIEW

7.2 SERVICES

7.3 PRODUCT

7.3.1 CHO-DXB11

7.3.2 CHO-K1

7.3.2.1 CHO-K1 ATCC

7.3.2.2 CHO-K1 ECACC

7.3.2.3 OTHERS

7.3.3 CHO-DG44

7.3.4 CHO-S

7.3.5 OTHERS

8 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM

8.1 OVERVIEW

8.2 METABOLIC SELECTION SYSTEM

8.3 ANTIBIOTIC SELECTION SYSTEM

8.4 OTHERS

9 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 BIOLOGICS

9.2.1 MONOCLONAL ANTIBODIES

9.2.2 ENZYMES

9.2.3 CYTOKINES

9.2.4 CLOTTING FACTORS

9.2.5 HORMONES

9.2.6 FC-FUSION PROTIEN

9.2.7 OTHERS

9.3 MEDICAL RESEARCH

10 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER

10.1 OVERVIEW

10.2 BIOPHARMACEUTICAL COMPANIES

10.2.1 MEDIUM

10.2.2 SMALL

10.3 BIOTECHNOLOGY COMPANIES

10.3.1 MEDIUM

10.3.2 SMALL

10.4 CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS

10.4.1 MEDIUM

10.4.2 SMALL

10.5 CLINICAL RESEARCH ORGANIZATIONS

10.5.1 MEDIUM

10.5.2 SMALL

10.6 ACADEMIC INSTITUTES AND RESEARCH ORGANIZATIONS

10.7 OTHERS

11 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDERS

11.3 RETAIL SALES

11.4 OTHERS

12 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY COUNTRY

12.1 ASIA-PACIFIC

12.1.1 CHINA

12.1.2 JAPAN

12.1.3 INDIA

12.1.4 AUSTRALIA

12.1.5 SOUTH KOREA

12.1.6 NEW ZEALAND

12.1.7 SINGAPORE

12.1.8 THAILAND

12.1.9 PHILIPPINES

12.1.10 MALAYSIA

12.1.11 INDONESIA

12.1.12 VIETNAM

12.1.13 TAIWAN

12.1.14 REST OF ASIA-PACIFIC

13 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 SARTORIUS AG

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENT

15.2 LONZA

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 MERCK KGAA

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENT

15.4 CYTIVA

15.4.1 COMPANY SNAPSHOT

15.4.2 PRODUCT PORTFOLIO

15.4.3 RECENT DEVELOPMENT

15.5 THERMO FISHER SCIENTIFIC INC.

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT

15.6 ABEOMICS

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 ACCEGEN

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 APPLIED BIOLOGICAL MATERIALS INC. (ABM)

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENT

15.9 ATCC

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 BPS BIOSCIENCE, INC.

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 CLS CELL LINES SERVICE GMBH

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 CURIA GLOBAL, INC.

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.13 GENTARGET INC.

15.13.1 COMPANY SNAPSHOT

15.13.2 PRODUCT PORTFOLIO

15.13.3 RECENT DEVELOPMENT

15.14 HORIZON DISCOVERY LTD.

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 PROMEGA CORPORATION

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 RAYBIOTECH LIFE, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

List of Table

TABLE 1 ICH GUIDELINES FOR CHO CELL-BASED PRODUCTS

TABLE 2 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2022-2030 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 15 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 CHINA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 CHINA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 18 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 19 CHINA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 20 CHINA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 21 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 22 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 23 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 24 CHINA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 25 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 26 CHINA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 27 CHINA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 28 CHINA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 29 CHINA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 30 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 31 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 32 JAPAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 33 JAPAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 34 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 35 JAPAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 JAPAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 37 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 38 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 39 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 40 JAPAN BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 41 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 42 JAPAN BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 JAPAN BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 JAPAN CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 JAPAN CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 46 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 47 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 INDIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 INDIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 50 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 51 INDIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 INDIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 53 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 54 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 55 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 56 INDIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 57 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 58 INDIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 INDIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 INDIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 INDIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 63 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 AUSTRALIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 AUSTRALIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 66 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 67 AUSTRALIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 68 AUSTRALIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 69 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 70 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 71 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 72 AUSTRALIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 73 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 74 AUSTRALIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 AUSTRALIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 76 AUSTRALIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 AUSTRALIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 79 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 SOUTH KOREA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 SOUTH KOREA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 82 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 83 SOUTH KOREA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 SOUTH KOREA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 85 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 86 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 87 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 88 SOUTH KOREA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 89 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 90 SOUTH KOREA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 SOUTH KOREA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 SOUTH KOREA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 SOUTH KOREA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 94 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 95 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 96 NEW ZEALAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 NEW ZEALAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 98 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 99 NEW ZEALAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 NEW ZEALAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 101 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 102 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 103 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 104 NEW ZEALAND BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 105 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 106 NEW ZEALAND BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 NEW ZEALAND BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 108 NEW ZEALAND CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 NEW ZEALAND CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 110 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 111 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 SINGAPORE PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 SINGAPORE PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 114 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 115 SINGAPORE CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 SINGAPORE CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 117 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 118 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 119 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 120 SINGAPORE BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 121 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 122 SINGAPORE BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 SINGAPORE BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 SINGAPORE CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 SINGAPORE CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 126 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 127 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 THAILAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 THAILAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 130 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 131 THAILAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 132 THAILAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 133 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 134 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 135 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 136 THAILAND BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 137 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 138 THAILAND BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 THAILAND BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 THAILAND CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 THAILAND CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 142 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 143 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 PHILIPPINES PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 PHILIPPINES PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 146 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 147 PHILIPPINES CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 PHILIPPINES CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 149 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 150 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 151 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 152 PHILIPPINES BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 153 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 154 PHILIPPINES BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 PHILIPPINES BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 PHILIPPINES CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 PHILIPPINES CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 158 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 159 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 MALAYSIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 MALAYSIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 162 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 163 MALAYSIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 MALAYSIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 165 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 166 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 167 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 168 MALAYSIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 169 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 170 MALAYSIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 MALAYSIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 MALAYSIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 MALAYSIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 174 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 INDONESIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 INDONESIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 178 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 179 INDONESIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 INDONESIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 181 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 182 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 183 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 184 INDONESIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 185 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 186 INDONESIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 INDONESIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 INDONESIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 INDONESIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 191 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 192 VIETNAM PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 VIETNAM PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 194 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 195 VIETNAM CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 196 VIETNAM CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 197 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 198 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 199 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 200 VIETNAM BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 201 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 202 VIETNAM BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 203 VIETNAM BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 VIETNAM CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 VIETNAM CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 206 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 207 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 TAIWAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 TAIWAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 210 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 211 TAIWAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 TAIWAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP

TABLE 213 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 214 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)

TABLE 215 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 216 TAIWAN BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 217 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 218 TAIWAN BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 219 TAIWAN BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 TAIWAN CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 TAIWAN CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 222 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 223 REST OF ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: SEGMENTATION

FIGURE 11 GROWING DEMAND FOR BIOPHARMACEUTICALS IS EXPECTED TO DRIVE THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET IN THE FORECAST PERIOD OF 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET

FIGURE 14 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2022

FIGURE 15 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 16 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 17 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2022

FIGURE 19 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2023-2030 (USD THOUSAND)

FIGURE 20 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, CAGR (2023-2030)

FIGURE 21 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, LIFELINE CURVE

FIGURE 22 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2022

FIGURE 23 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)

FIGURE 24 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 25 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 26 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2022

FIGURE 27 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 28 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2022

FIGURE 31 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 32 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET SNAPSHOT

FIGURE 35 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Chinese Hamster Ovary (CHO) cells market size will be worth USD 159,123.92 Thousand by 2030.
The growth rate of the Asia-Pacific Chinese Hamster Ovary (CHO) cells market is 9.9% in the forecast by 2030.
Rising use of cho cells in genetic study & growing demand for biopharmaceuticals are the growth drivers of the Asia-Pacific Chinese Hamster Ovary (CHO) cells market.
Type, system, application, end-user, and distribution channel are the factors on which the Asia-Pacific Chinese Hamster Ovary (CHO) cells market research is based.
Major companies in the Asia-Pacific Chinese Hamster Ovary (CHO) cells market are Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others.